Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + bevacizumab + CapeOX for HER2-positive advanced colorectal cancer
ChiCTR2100043766Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib in colorectal cancer (CRC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective remission rate. Started Jan 2021; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100043766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043766.